Vijay Sankaran led research showing rs17834140-T reduces myeloid malignancy risk by 20%. GWAS study analyzed 640,000 people to link aging-related mutations to clonal hematopoiesis. Gene-editing experiments showed rs17834140-T disrupts GATA-2 binding site, lowering MSI2. Carriers with one copy of rs17834140-T are 1.8x more likely to lose clones. MSI2 downregulation remains challenging despite therapeutic potential. Clonal hematopoiesis carries 60% blood cancer risk over 5–10 years